RA CAPITAL MANAGEMENT, L.P. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Boston, MA
SEC filing record 1 source field available
Fiscal year end
31 December
RA CAPITAL MANAGEMENT, L.P. has filed 1,716 SEC EDGAR filings since 14 Dec 2005

SEC filing history

Showing 251-275 of 668 matching filings.

Per page
25
Current page
11
SC 13G/A

SC 13G/A

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

LARIMAR THERAPEUTICS, INC.

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

KALVISTA PHARMACEUTICALS, INC.

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

CYTEIR THERAPEUTICS, INC.

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
10 Jan 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
22 Dec 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
20 Dec 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
19 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE 13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE 13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE 13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE 13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE 13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A

SCHEDULE 13G/A

Filing date
15 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
05 Nov 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
25 Oct 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
25 Oct 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
01 Oct 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

AERPIO PHARMACEUTICALS, INC.

Filing date
23 Aug 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
16 Aug 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

EYEPOINT PHARMACEUTICALS, INC.

Filing date
13 Aug 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
13 Aug 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
09 Aug 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .